Effect of GluA1 interacting proteins GNAI2 and SRSF10 on prognosis of Hepatocellular carcinoma and establishment of diagnostic model

Zhang Mingming; Yi Faping

doi:10.13406/j.cnki.cyxb.003391

您当前的位置：

首页 >

文章列表页 >

Effect of GluA1 interacting proteins GNAI2 and SRSF10 on prognosis of Hepatocellular carcinoma and establishment of diagnostic model

Disease data analysis and modeling | 更新时间：2025-10-22

- Effect of GluA1 interacting proteins GNAI2 and SRSF10 on prognosis of Hepatocellular carcinoma and establishment of diagnostic model
- Journal of Chongqing Medical University Vol. 48, Issue 12, Pages: 1408-1417(2023)
- 作者机构：
  
  重庆医科大学基础医学院生物化学与分子生物学教研室，重庆 400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003391
  CLC： R735.7;R34
- Received：12 October 2023，
  
  Revised：2023-11-22，
  
  Accepted：08 December 2023，
  
  Published：28 December 2023
- 稿件说明：
移动端阅览
张洺铭,易发平.GluA1相互作用蛋白GNAI2和SRSF10对肝细胞癌预后的影响及诊断模型的建立[J].重庆医科大学学报,2023,48(12):1408-1417.

Zhang Mingming,Yi Faping.Effect of GluA1 interacting proteins GNAI2 and SRSF10 on prognosis of Hepatocellular carcinoma and establishment of diagnostic model[J].Journal of Chongqing Medical University,2023,48(12):1408-1417.
张洺铭,易发平.GluA1相互作用蛋白GNAI2和SRSF10对肝细胞癌预后的影响及诊断模型的建立[J].重庆医科大学学报,2023,48(12):1408-1417. DOI： 10.13406/j.cnki.cyxb.003391.

Zhang Mingming,Yi Faping.Effect of GluA1 interacting proteins GNAI2 and SRSF10 on prognosis of Hepatocellular carcinoma and establishment of diagnostic model[J].Journal of Chongqing Medical University,2023,48(12):1408-1417. DOI： 10.13406/j.cnki.cyxb.003391.

摘要

目的

探讨AMPA型谷氨酸受体亚基1（glutamate A1，GluA1）相互作用蛋白GNAI2、SRSF10对HCC药物相关靶点、预后指标及诊断模型的作用和影响。

方法

蛋白质组学方法获得GluA1相互作用蛋白。Xena数据库（

https：//xenabrowser.net/

https://xenabrowser.net/

）中获取肝细胞癌（liver hepatocellular carcinoma，LIHC）转录组数据以及对应的临床数据，保留在75%样本中表达的基因和其中原发肿瘤和癌旁组织样本用于后续分析。R语言的limma包标准流程对样本进行差异分析。对GluA1相互作用蛋白及差异基因取交集，并进行表达量分析、单因素COX分析和生存曲线分析。PDBePISA数据库验证候选蛋白集与GluA1在分子结构上的对接。string数据库分析候选蛋白集与肝癌相关药物的作用靶点。多因素COX分析患者的预后指标，logistic回归模型构建肝癌诊断模型。

结果

获得6个候选蛋白，即KIF1A、GNAI2、RPL3、ARPC1A、EIF3H和SRSF10与GluA1具有很强的亲和力。其中GNAI2和SRSF10是肝细胞癌药物Regorafenib的二级作用靶点，其在单因素以及多因素COX分析中对患者的生存均存在影响（

0.05），GNAI2（

=0.000 339），SRSF10（

=0.040 4），并且GNAI2、SRSF10在疾病组中比正常组中高。

值分别为GNAI2：3.584、SRSF10：2.049。HR分别为GNAI2：2.38，SRSF10：1.18，均为不利预后因素，有希望作为独立于其他因素的预后指标。在肝癌患者的诊断模型中，HR系数分别为GNAI2：11.8455，SRSF10：-0.2037，且该模型在训练集上的曲线下面积为0.971，性能优异。

结论

GluA1相互作用蛋白GNAI2和SRSF10是肝细胞癌治疗药物Regorafenib的二级作用靶点，意味着其可能会成为独立于其他因素的预后指标，且具备一定的诊断意义。

Abstract

Objective

To investigate the effect of AMPA glutamate receptor subunit 1（glutamate A1，GluA1） interacting proteins GNAI2 and SRSF10 on drug-related targets，prognostic indicators，and diagnostic models of hepatocellular carcinoma（HCC）.

Methods

GluA1 interacting proteins were obtained by proteomic methods. Transcriptome data and the corresponding clinical data of liver hep

atocellular carcinoma were obtained from the Xena database（

https：//xenabrowser.net/

https://xenabrowser.net/

）. Genes expressed in 75% of the samples and primary tumor and para-carcinoma tissue samples were retained for subsequent analysis. The limma package standard process in R language was used to perform variation analysis on the samples. The intersection of GluA1 interacting proteins and differentially expressed genes was obtained for expression analysis，univariate COX analysis，and survival curve analysis. The PDBePISA database was used to verify the molecular docking of the candidate protein set with GluA1. The string database was used to analyze the targets of HCC-related drugs in the candidate protein set. Prognostic indicators of patients were analyzed by the multivariate COX analysis. The logistic regression model was used to construct a diagnostic model for HCC.

Results

Six candidate proteins，namely KIF1A，GNAI2，RPL3，ARPC1A，EIF3H，and SRSF10，were obtained with strong affinity to GluA1. GNAI2 and SRSF10 were secondary targets of Regorafenib in HCC，and the univariate and multivariate COX analyses showed that they had significant effects on patient survival（

=0.000 339，0.0404）. GNAI2 and SRSF10 were higher in level in the disease group than in the normal group（

=3.584，2.049； hazard ratio（HR）=2.38，1.18），and are adverse prognostic factors. In the diagnostic model of HCC，the HR coefficients were 11.8455 and -0.2037，respectively，and the area under the curve of this model on the training set was 0.971，indicating excellent performances.

Conclusion

GluA1 interacting proteins GNAI2 and SRSF10 are secondary targets of Regorafenib in HCC，which may become prognostic indicators independent of other factors and have certain diagnostic significance.

关键词

Keywords

references

Wu QL ， Gao Y ， Li JT ， et al . The role of AMPARs composition and trafficking in synaptic plasticity and diseases [J ] . Cell Mol Neurobiol ， 2022 ， 42 （ 8 ）： 2489 - 2504 ．

Mishra S ， Knupp A ， Szabo MP ， et al . The Alzheimer’s gene SORL1 is a regulator of endosomal traffic and recycling in human neurons [J ] . Cell Mol Life Sci ， 2022 ， 79 （ 3 ）： 162 ．

Liu YC ， Zhang MM ， Liu Z ， et al . A strategy can be used to analyze intracellular interaction proteomics of cell-surface receptors [J ] . Amino Acids ， 2023 ， 55 （ 2 ）： 263 - 273 .

Nagtegaal ID ， Odze RD ， Klimstra D ， et al . The 2019 WHO classification of tumours of the digestive system [J ] . Histopathology ， 2020 ， 76 （ 2 ）： 182 - 188 ．

Bray F ， Ferlay J ， Soerjomataram I ， et al . Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2018 ， 68 （ 6 ）： 394 - 424 ．

Xia CF ， Dong XS ， Li H ， et al . Cancer statistics in China and United States，2022：profiles，trends，and determinants [J ] . Chin Med J ， 2022 ， 135 （ 5 ）： 584 - 590 ．

Liu ZQ ， Xu KL ， Jiang YF ， et al . Global trend of aetiology-based primary liver cancer incidence from 1990 to 2030：a modelling study [J ] . Int J Epidemiol ， 2021 ， 50 （ 1 ）： 128 - 142 ．

Llovet JM ， Kelley RK ， Villanueva A ， et al . Hepatocellular carcinoma [J ] . Nat Rev Dis Primers ， 2021 ， 7 ： 6 ．

Killock D . Liver cancer：regorafenib-a new RESORCE in HCC [J ] . Nat Rev Clin Oncol ， 2017 ， 14 （ 2 ）： 70 - 71 ．

Venkataramani V ， Tanev DI ， Strahle C ， et al . Glutamatergic synaptic input to glioma cells drives brain tumour progression [J ] . Nature ， 2019 ， 573 （ 7775 ）： 532 - 538 ．

Zhang JF ， Li J ， Yin YC ， et al . Collapsin response mediator protein 2 and endophilin2 coordinate regulation of AMPA receptor GluA1 subunit recycling [J ] . Front Mol Neurosci ， 2020 ， 13 : 128 .

Miller BM ， Oderberg IM ， Goessling W . Hepatic nervous system in development，regeneration，and disease [J ] . Hepatology ， 2021 ， 74 （ 6 ）： 3513 - 3522 ．

Mizuno K ， Ueno Y . Autonomic nervous system and the liver [J ] . Hepatol Res ， 2017 ， 47 （ 2 ）： 160 - 165 ．

Huan HB ， Wen XD ， Chen XJ ， et al . Sympathetic nervous system promotes hepatocarcinogenesis by modulating inflammation through activation of alpha1-adrenergic receptors of Kupffer cells [J ] . Brain Behav Immun ， 2017 ， 59 ： 118 - 134 ．

Yu J ， Rao P ， Clark S ， et al . Hippocampal AMPA receptor assemblies and mechanism of allosteric inhibition [J ] . Nature ， 2021 ， 594 （ 7863 ）： 448 - 453 ．

Zhang TY ， Cai MT ， Zheng Y ， et al . Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis：a review [J ] . Front Immunol ， 2021 ， 12 ： 652820 ．

Alqahtani A ， Khan Z ， Alloghbi A ， et al . Hepatocellular carcinoma：molecular mechanisms and targeted therapies [J ] . Medicina ， 2019 ， 55 （ 9 ）： 526 ．

Bruix J ， Qin SK ， Merle P ， et al . Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment （RESORCE）：a randomised，double-blind，placebo-controlled，phase 3 trial [J ] . Lancet ， 2017 ， 389 （ 10064 ）： 56 - 66 ．

Bush KT ， Boichard A ， Tsigelny IF . In vitro elucidation of drug combination synergy in treatment of pancreatic ductal adenocarcinoma [J ] . Anticancer Res ， 2018 ， 38 （ 4 ）： 1967 - 1977 ．

Katopodis P ， Kerslake R ， Zikopoulos A ， et al . p38β - MAPK11 and its role in female cancers [J ] . J Ovarian Res ， 2021 ， 14 （ 1 ）： 84 ．

Yao ZC ， Xu RY ， Yuan L ， et al . Circ_0001955 facilitates hepatocellular carcinoma （HCC） tumorigenesis by sponging miR-516a-5p to release TRAF6 and MAPK11 [J ] . Cell Death Dis ， 2019 ， 10 （ 12 ）： 945 ．

Qian YQ ， Daza J ， Itzel T ， et al . Prognostic cancer gene expression signatures：current status and challenges [J ] . Cells ， 2021 ， 10 （ 3 ）： 648 ．

Gholizadeh M ， Mazlooman SR ， Hadizadeh M ， et al . Detection of key mRNAs in liver tissue of hepatocellular carcinoma patients based on machine learning and bioinformatics analysis [J ] . MethodsX ， 2023 ， 10 ： 102021 ．

Li ZW ， Sun BC ， Gong T ， et al . GNAI1 and GNAI3 reduce colitis-associated tumorigenesis in mice by blocking IL6 signaling and down-regulating expression of GNAI2 [J ] . Gastroenterology ， 2019 ， 156 （ 8 ）： 2297 - 2312 ．

Hu SS ， Dai YY ， Bai SC ， et al . GNAI2 promotes proliferation and decreases apoptosis in rabbit melanocytes [J ] . Genes ， 2021 ， 12 （ 8 ）： 1130 ．

Lu Y ， Xi J ， Zhang Y ， et al . SNHG1 inhibits ox-LDL-induced inflammatory response and apoptosis of HUVECs via up-regulating GNAI2 and PCBP1 [J ] . Front Pharmacol ， 2020 ， 11 ： 703 ．

Sun QK ， He QF ， Xu JB ， et al . Guanine nucleotide-binding protein G（i）α2 aggravates hepatic ischemia-reperfusion injury in mice by regulating MLK3 signaling [J ] . FASEB J ， 2019 ， 33 （ 6 ）： 7049 - 7060 ．

Zhang SY ， Wang H ， Liu J ， et al . RGS1 and related genes as potential targets for immunotherapy in cervical cancer：computational biology and experimental validation [J ] . J Transl Med ， 2022 ， 20 （ 1 ）： 334 ．

Chen MB ， Li ZF ， Gu CT ， et al . Identification of G protein subunit alpha i2 as a promising therapeutic target of hepatocellular carcinoma [J ] . Cell Death Dis ， 2023 ， 14 （ 2 ）： 143 ．

Chang CJ ， Rajasekaran M ， Qiao YT ， et al . The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma [J ] . Nat Commun ， 2022 ， 13 （ 1 ）： 1363 ．

Li JJ ， Jiang HY ， Mu YW ， et al . SRSF10 regulates proliferation of neural progenitor cells and affects neurogenesis in developing mouse neocortex [J ] . iScience ， 2023 ， 26 （ 7 ）： 107042 ．

Liu XM ， Zheng YQ ， Xiao MQ ， et al . SRSF10 stabilizes CDC25A by triggering exon 6 skipping to promote hepatocarcinogenesis [J ] . J Exp Clin Cancer Res ， 2022 ， 41 （ 1 ）： 353 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research advances in yttrium-90 microsphere selective internal radiation therapy in treatment of hepatocellular carcinoma

Effect of circulating plasma cell on the prognosis of patients with multiple myeloma

Effect of DExH-box helicase 9 O-GlcNAc modification on the proliferation of HBV-associated hepatoma cells

Prognostic study of ¹⁸F-FDG PET/CT combined with clinical characteristics in treated patients with esophageal squamous cell carcinoma

Association between albumin-corrected anion gap and prognosis in patients with acute pancreatitis: a retrospective cohort study

Related Author

Chen Honglin

Zhang Han

Zhu Xinyue

Yang Zhicheng

Tan Maoting

Zhao Yongle

Zhao Hongyun

Wang Lulu

Related Institution

Department of Gastroenterology， The Second Affiliated Hospital of Chongqing Medical University

Department of Hematology，the First Affiliated Hospital of Air Force Medical University

Key Laboratory of Molecular Biology on Infectious Diseases， Ministry of Education，Chongqing Medical University

Department of Nuclear Medicine，The First Affiliated Hospital of Chongqing Medical University

Department of Critical Care Medicine，The Seventh People’s Hospital，Shanghai University of Traditional Chinese Medicine

⁰